Latigo Biotherapeutics, Inc. (LTGO)

NASDAQ: LTGO · USD

$15.7

+0.53 (+3.5%)· Recorded snapshot

Market cap	1B
Net income (ttm)	-111.1M
EPS (ttm)	-$117
Shares out	66.3M
Volume	150,851

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -111.1M
EPS (ttm): -$117
Market cap: 1B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All LTGO indicators

Market & fundamental data

Available fields

137

Groups with data

Currency

USD

Showing 137 of 137 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002056611
Company name	Latigo Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	517954103
Earnings date	2026-11-19
Earnings time	bmo
Employees	66
Enterprise value	$1B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-08-08
Fiscal year end	December
Founded	2018
Industry	Biotechnology
IPO date	2026-08-07
Is primary listing	Yes
Is SPAC	No
ISIN number	US5179541033
Last earnings date	2026-09-03
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1B
Market cap category	Small-Cap
Next earnings date	2026-11-19
Options	No
Price	$15.74
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	LTGO
U.S. state	California
Website	https://latigobio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-741.68%
FCF / EV yield	-10.41%
FCF yield	-10.17%
P/B ratio	81.24x
Sector forward P/E	23.56x
Sector P/E	50.09x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.7M
ROCE	-852.32%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-111,000
Depreciation and amortization	$215,000
EBIT	$-112.4M
EBITDA	$-112.2M
EPS	$-116.74
FCF per share	$-1.56
Financing cash flow	$84M
Free cash flow	$-103.3M
Free cash flow minus SBC	$-111M
Investing cash flow	$-111,000
Net borrowing	$35M
Net cash flow	$-19.3M
Net income	$-111.1M
Operating cash flow minus SBC	$-110.9M
Operating income	$-112.4M
Stock-based compensation	$7.7M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$-279.37
Debt / equity	2.5
Interest coverage	-447.73
Long-term assets	$5.6M
Long-term liabilities	$683,000
Net cash (debt)	$23.8M
Net cash / market cap	2.34%
Net debt / equity	-1.9
Piotroski F-Score	1
Property, plant and equipment	$1.8M
Shareholders' equity	$12.5M
Tangible book value	$-276.1M
Tangible book value per share	$-279.37
Total assets	$64.8M
Total cash	$55M
Total debt	$31.3M
Total liabilities	$52.3M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$59.2M
Current liabilities	$51.6M
Current ratio	1.15
Net working capital	$-16.8M
Quick ratio	1.07
Working capital	$7.6M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	3.48%
1M price change	-8.78%
1M total return	-8.78%
1W price change	2.59%
1W total return	2.59%
20-day SMA	$15.49
50-day SMA	$19.17
52-week high	$25.93
52-week high date	2026-08-27
52-week low	$13.50
52-week low date	2026-10-15
All-time high	$25.93
All-time high date	2026-08-27
All-time low	$13.50
All-time low date	2026-10-15
Average true range (ATR)	$1.35
Average volume	249.7K
Beta (1Y)	-2.02
Change from 52-week high	-39.3%
Change from 52-week low	16.61%
Change from all-time high	-39.66%
Change from all-time low	15.91%
Change from open	0.83%
Day's gap	2.63%
Dollar volume	$2.4M
High price	$15.80
Low price	$15.32
Monthly RSI	0
Open price	$15.61
Position in 52-week range	87.5%
Previous close	$15.21
Price vs 20-day SMA	0.97%
Price vs 50-day SMA	-18.4%
Relative volume	0.6
Return from IPO open	-27.05%
Return from IPO price	-14.89%
RSI	45.41
Sharpe ratio	-0.61
Sortino ratio	-0.71
Volume	150.9K
Weekly RSI	0

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	21.7M
Float percentage	32.8%
Shares change (QoQ)	2.88%
Shares held by insiders	6.52%
Shares held by institutions	8.28%
Shares outstanding	66.3M
Short % of float	3.83%
Short % of shares	1.26%
Short ratio	2.3 days

Deeper analysis on LTGO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this LTGO report

Is a complete LTGO research report available?

No complete published report is available for Latigo Biotherapeutics, Inc. (LTGO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Latigo Biotherapeutics, Inc. (LTGO)

Price

Financial snapshot

Fair-value bridge

Latest news · LTGO

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All LTGO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on LTGO

Frequently asked questions